Phase II study of pre-emptive therapy against CMV-associated disesase by valganciclovir after allogeneic hematopoietic stem cell transplantatio
Phase 2
- Conditions
- Patients with CMV reactivation after allogeneic hematopoietic stem cell transplantation
- Registration Number
- JPRN-UMIN000000953
- Lead Sponsor
- Dept of 1st Intern Med, Kyushu Univ Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Negative CMV-Ab of both donor and recipient cord blood transplantion T-cell depleted or CD34-positive cell selected transplantion Gut GVHD (>=stage 2) HLA more than 2 locus disparity
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of valganciclovir against CMV reactivation
- Secondary Outcome Measures
Name Time Method Safety of valganciclovir after allogeneic HSCT Incidence of CMV-associated disease